Myocardial perfusion imaging method
AssigneeCV Therapeutics, Inc.
InventorsLuiz Belardinelli, Brent K. Blackburn, Zhenhai Gao
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for using the partial adenosine A2A receptor agonists having the following structure in myocardiological perfusion imaging.
Claims22
A method of myocardial perfusion imaging of a mammal in need thereof, comprising administering a radionuclide and a dose of a compound that is a selective partial A2A adenosine receptor agonist with a short duration of action to a mammal in need thereof, and determining areas of insufficient blood flow, wherein the selective partial A2A adenosine receptor agonist is CVT-3033, also known as (4S,2R,3R,5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9-yl]-5-(hydroxymethyl) oxolane-3,4-diol, or CVT-3146, also known as (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, and wherein the dose is from 0.0002 to 0.009 mg/kg.
A method for iincreasing coronary blood flow in a mammal in need there of comprising administering a pharmaceutically effective amount of a partial A2A adenosine receptor agonist to a mammal, wherein the selective partial A2A adenosine receptor agonist is CVT-3033, also known as (4S,2R,3R,5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9-yl]-5-(hydroxymethyl) oxolane-3,4-diol, or CVT-3146, also known as (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxola-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, and wherein the pharmaceutically effective amount is from 0.0002 to 0.009 mg/kg.
A method of myocardial perfusion imaging of a mannnal in need thereof, comprising administering a radionuclide and a dose of a compound that is a selective partial A2A adenosine receptor agonist with a short duration of action to a mammal in need thereof, and determining areas of insufficient blood flow, wherein the selective partial A2A adenosine receptor agonist is CVT-3146, also known as (1-{9-[(4S,2R,3R,5R)-dihydroxy-5-(hydroxymethyl)oxola-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl) and wherein the dose is from 0.0002 to 0.009 mg/kg.
A method for increasing coronary blood flow in a mammal in need there of comprising administering a pharmaceutically effective amount of a partial A2A adenosine receptor agonist to the mammal, wherein the selective partial A2A adenosine receptor agonist is CVT-3033, also known as (4S,2R,3R,5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9-yl]-5-(hydroxymethyl) oxolane-3,4-diol, or CVT-3146, also known as (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxola-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, wherein the pharmaceutically effective amount is from 0.0002 to 0.009 mg/kg.
Dependencies are inferred from the claim text.